ZNTL Zentalis Pharmaceuticals, Inc. Stock Quote

ZNTL [NASD]

Index	-	P/E	-	EPS (ttm)	-3.85	Insider Own	4.60%	Shs Outstand	45.00M	Perf Week	-21.83%
Market Cap	1.23B	Forward P/E	-	EPS next Y	-4.71	Insider Trans	-11.34%	Shs Float	31.80M	Perf Month	-13.15%
Income	-167.90M	PEG	-	EPS next Q	-1.21	Inst Own	80.70%	Short Float	13.59%	Perf Quarter	-56.53%
Sales	-	P/S	-	EPS this Y	11.30%	Inst Trans	2.99%	Short Ratio	5.40	Perf Half Y	-72.27%
Book/sh	8.09	P/B	2.56	EPS next Y	-8.00%	ROA	-39.70%	Target Price	82.40	Perf Year	-63.37%
Cash/sh	5.74	P/C	3.61	EPS next 5Y	-	ROE	-47.70%	52W Range	17.33 - 87.19	Perf YTD	-75.34%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-76.22%	Beta	-
Dividend %	-	Quick Ratio	8.00	Sales past 5Y	-	Gross Margin	-	52W Low	19.62%	ATR	2.70
Employees	177	Current Ratio	8.00	Sales Q/Q	-	Oper. Margin	-	RSI (14)	38.68	Volatility	11.66% 12.57%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-10.50%	Profit Margin	-	Rel Volume	0.47	Prev Close	20.73
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Feb 24 BMO	Payout	-	Avg Volume	800.17K	Price	20.73
Recom	1.40	SMA20	-10.73%	SMA50	-36.56%	SMA200	-64.39%	Volume	0	Change	0.00%

Apr-06-22

Initiated

Wells Fargo

Overweight

$67

Oct-07-21

Resumed

Jefferies

Buy

$120

Sep-30-21

Initiated

Stifel

Buy

$84

Sep-29-21

Initiated

Oppenheimer

Outperform

$90

May-21-21

Initiated

UBS

Buy

$91

Jan-20-21

Initiated

Wedbush

Outperform

$65

Sep-29-20

Initiated

Cantor Fitzgerald

Overweight

$44

Aug-27-20

Initiated

H.C. Wainwright

Buy

$43

Apr-28-20

Initiated

SVB Leerink

Outperform

$45

Apr-28-20

Initiated

Morgan Stanley

Overweight

$45

Apr-28-20

Initiated

Jefferies

Buy

$41

Apr-28-20

Initiated

Guggenheim

Buy

$45

May-21-22 09:48AM	What Percentage Of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Do Insiders Own? Simply Wall St.
May-18-22 04:01PM	Zentalis Pharmaceuticals Announces Closing of Underwritten Offering of Common Stock GlobeNewswire -9.24%
May-16-22 07:28AM	Zentalis Pharmaceuticals Announces Pricing of Underwritten Offering of Common Stock GlobeNewswire +18.90%
07:00AM	Zentalis Pharmaceuticals Appoints Oncology Clinical Development Veteran Dr. Kimberly Blackwell as Chief Executive Officer GlobeNewswire
May-05-22 07:00AM	Zentalis Pharmaceuticals Reports First Quarter 2022 Financial Results and Operational Update GlobeNewswire -6.71%
Apr-27-22 10:17AM	Pfizer Injects $25M Via Equity In Zentalis Pharma Benzinga +11.77%
07:00AM	Zentalis Pharmaceuticals Announces $25 Million Equity Investment from Pfizer GlobeNewswire
Apr-19-22 09:35AM	Here's Why Zentalis Pharmaceuticals, Inc. (ZNTL) is Poised for a Turnaround After Losing 50% in 4 Weeks Zacks
Apr-11-22 04:01PM	Zentalis Pharmaceuticals Announces Overview of Clinical and Preclinical Data Presented at AACR GlobeNewswire -8.10%
07:22AM	Zentalis Pharma Posts Initial Clinical Data On Its Wee1 Inhibitor In Ovarian Cancer Benzinga
Apr-08-22 01:00PM	Zentalis Pharmaceuticals Announces Positive Initial Clinical Data on ZN-c3, its Wee1 Inhibitor, in Patients with Advanced Ovarian Cancer at AACR GlobeNewswire -30.02%
Mar-29-22 07:00AM	Zentalis Pharmaceuticals and Caris Life Sciences Announce Strategic Collaboration to Support Clinical Studies, Initially Focused on the Wee1 Inhibitor ZN-c3 GlobeNewswire +6.54%
Mar-22-22 07:00AM	Zentalis Pharmaceuticals Announces First Patient Dosed in the Potentially Registrational Phase 1/2 Study of BCL-2 inhibitor ZN-d5 in Patients with Relapsed or Refractory Light Chain (AL) Amyloidosis GlobeNewswire
Mar-09-22 04:01PM	Zentalis Pharmaceuticals to Present at the Oppenheimer Annual Healthcare Conference GlobeNewswire +9.66%
Mar-08-22 04:30PM	Zentalis Pharmaceuticals to Present New Clinical and Preclinical Data at the AACR Annual Meeting 2022 GlobeNewswire
Feb-24-22 07:00AM	Zentalis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update GlobeNewswire +6.73%
Feb-03-22 07:00AM	Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences GlobeNewswire
Dec-22-21 10:15AM	Zentalis Pharmaceuticals Inc (ZNTL) COO Kevin D. Bunker Sold $792,400 of Shares GuruFocus.com
Dec-21-21 12:03PM	We're Hopeful That Zentalis Pharmaceuticals (NASDAQ:ZNTL) Will Use Its Cash Wisely Simply Wall St.
Dec-14-21 11:15AM	Zentalis Pharmaceuticals Inc (ZNTL) COO Kevin D. Bunker Sold $717,100 of Shares GuruFocus.com
Dec-02-21 07:00AM	Zentalis Pharmaceuticals to Host Virtual Research and Development (R&D) Day on December 16, 2021 GlobeNewswire +6.51%
Nov-17-21 11:35AM	Zentalis Pharmaceuticals Insider Sold Over $750K In Company Stock Benzinga
07:00AM	Zentalis Pharmaceuticals Announces Fast Track Designation Granted by the U.S. FDA to ZN-c3 for the Treatment of Uterine Serous Carcinoma GlobeNewswire
Nov-10-21 07:00AM	Zentalis Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Update GlobeNewswire
Nov-09-21 07:00AM	Zentalis Pharmaceuticals to Present at Two Upcoming Investor Conferences GlobeNewswire
Nov-08-21 10:07AM	Director Of Zentalis Pharmaceuticals Makes $830K Sale Benzinga
Nov-03-21 11:26AM	Zentalis Pharmaceuticals Insider Trades $1.7M In Company Stock Benzinga
Oct-25-21 12:04PM	Hedge Funds Are Piling Into Zentalis Pharmaceuticals, Inc. (ZNTL) Insider Monkey
Oct-05-21 11:28AM	Zentalis Pharmaceuticals Insider Trades $1.8M In Company Stock Benzinga
Sep-13-21 07:00AM	Zentalis Pharmaceuticals Announces First Patient Dosed in the Phase 1/2 Study of ZN-c3 in Combination with Gemcitabine in Patients with Osteosarcoma GlobeNewswire
Sep-09-21 07:00AM	Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2021 GlobeNewswire
Sep-02-21 07:00AM	Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences GlobeNewswire
Sep-01-21 07:00AM	Zentalis Pharmaceuticals Announces Publication in the Journal of Medicinal Chemistry Highlighting the Discovery of its WEE1 Inhibitor Candidate ZN-c3 GlobeNewswire
Aug-12-21 07:00AM	Zentalis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update GlobeNewswire
Aug-04-21 07:00AM	Zentalis Pharmaceuticals to Participate in the Wedbush PacGrow Healthcare Virtual Conference GlobeNewswire
Aug-02-21 07:30AM	Zentalis Pharmaceuticals Announces First Patient Dosed in Potentially Registrational Phase 2 Study of ZN-c3 in Patients with Uterine Serous Carcinoma GlobeNewswire -5.71%
07:00AM	Zentera Therapeutics Announces Closing of $75 Million Series B Financing GlobeNewswire
Jul-28-21 01:15PM	Is ZNTL Stock A Buy or Sell? Insider Monkey
Jul-01-21 04:01PM	Zentalis Pharmaceuticals Announces Closing of Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Jun-29-21 06:54AM	Zentalis Secures $150M In Equity Funding Benzinga +8.55%
Jun-28-21 09:09PM	Zentalis Pharmaceuticals Announces Pricing of Offering of Common Stock GlobeNewswire
04:18PM	Zentalis Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire
07:00AM	Zentalis Pharmaceuticals Announces Updates Across its Pipeline Including Promising New Interim Clinical Data on ZN-c3 (WEE1i) and ZN-c5 (SERD) and Two Potentially Registrational Trials for ZN-c3, with the First Trial Already Initiated GlobeNewswire
Jun-22-21 07:16AM	We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth Simply Wall St.
Jun-21-21 09:15AM	Dave Johnson Joins Biosplice Therapeutics Board of Directors GlobeNewswire
May-28-21 07:00AM	Zentalis Pharmaceuticals to Participate in the Jefferies Virtual Healthcare Conference GlobeNewswire
May-17-21 07:00AM	Zentalis Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update GlobeNewswire -7.43%
Apr-20-21 08:00AM	Gain Therapeutics Announces Multi-Target Drug Discovery Collaboration Agreement with Zentalis Pharmaceuticals GlobeNewswire
Apr-12-21 11:18AM	Zentalis's Early WEE1 Inhibitor Data Shows 'Exceptional' Response In Solid Tumor Study, Plans Combination Trials Benzinga +8.05%
07:00AM	Zentalis Pharmaceuticals Enters into Clinical Collaboration and Supply Agreement with GlaxoSmithKline to Evaluate its Oral WEE1 Inhibitor, ZN-c3, in Combination with Niraparib, a PARP Inhibitor GlobeNewswire
Apr-10-21 01:30PM	Zentalis Pharmaceuticals Announces Promising Initial Data Presented in a Late-Breaking Session at AACR on ZN-c3, its WEE1 Inhibitor, in Patients with Advanced Solid Tumors GlobeNewswire
Mar-25-21 07:00AM	Zentalis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update GlobeNewswire
Mar-10-21 04:30PM	Zentalis Pharmaceuticals Announces Late-Breaker Oral Presentation on WEE1 Inhibitor, ZN-c3, at the AACR Annual Meeting 2021 GlobeNewswire
Feb-25-21 07:00AM	Zentalis Pharmaceuticals and Tempus Announce Strategic Collaboration to Advance Research and Development Capabilities GlobeNewswire
Feb-24-21 07:00AM	Zentalis Pharmaceuticals to Present Initial Clinical Data on ZN-c3 at the AACR Annual Meeting 2021 GlobeNewswire +11.43%
Feb-10-21 07:00AM	Zentalis Pharmaceuticals Announces the Appointment of Dr. Enoch Kariuki to its Board of Directors GlobeNewswire
Feb-05-21 07:00AM	Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences GlobeNewswire
Feb-04-21 08:41AM	Why Earnings Season Could Be Great for Zentalis (ZNTL) Zacks
Jan-06-21 07:00AM	Zentalis Pharmaceuticals Announces the Initiation of Multiple Early-Stage Clinical Trials GlobeNewswire -6.54%
Dec-23-20 05:20AM	Who Has Been Buying Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares? Simply Wall St. +8.12%
Dec-12-20 10:19PM	Is ZNTL A Good Stock To Buy Now? Insider Monkey
Nov-12-20 07:00AM	Zentalis Pharmaceuticals to Participate In Two Upcoming Investor Conferences GlobeNewswire
Nov-09-20 07:00AM	Zentalis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Update GlobeNewswire -8.70%
Sep-23-20 01:59PM	What Kind Of Investors Own Most Of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)? Simply Wall St.
Sep-11-20 07:00AM	Zentalis Pharmaceuticals to Host a Key Opinion Leader Virtual Meeting to Discuss its Investigational WEE1 Inhibitor ZN-c3 and its Potential as a Best-in-Class Treatment for Advanced Solid Tumors GlobeNewswire
Sep-10-20 07:00AM	Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences GlobeNewswire
Sep-01-20 07:00AM	Zentalis Pharmaceuticals Appoints Alexis Pinto as Chief Legal Officer GlobeNewswire -7.35%
Aug-13-20 07:00AM	Zentalis Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Update GlobeNewswire
Jul-29-20 09:11PM	Zentalis Pharmaceuticals Announces Pricing of Upsized Offering of Common Stock GlobeNewswire
Jul-27-20 04:19PM	Zentalis Pharmaceuticals Announces Proposed Public Offering of Common Stock GlobeNewswire
07:00AM	Zentalis Pharmaceuticals Enters into Clinical Collaboration with Eli Lilly and Company to Evaluate its Oral SERD ZN-c5 in Combination with Abemaciclib, a CDK4 and 6 Inhibitor GlobeNewswire
Jul-01-20 07:00AM	Zentalis Pharmaceuticals Announces the Appointment of Dr. Kimberly Blackwell to its Board of Directors GlobeNewswire
Jun-15-20 04:30PM	Zentalis Pharmaceuticals to Present Preclinical Data on ZN-c5 at the Upcoming AACR Virtual Annual Meeting II GlobeNewswire +11.75%
Jun-03-20 07:07AM	Is It Too Late to Jump In on Zentalis? Motley Fool
May-28-20 04:05PM	Zentalis Pharmaceuticals to Participate in Jefferies Virtual Healthcare Conference GlobeNewswire
07:00AM	Zentalis Pharmaceuticals and Tavros Therapeutics Announce Strategic Platform Collaboration to Discover Next Generation Targeted Small Molecule Therapies GlobeNewswire
May-20-20 07:00AM	Zentalis Pharmaceuticals Announces $20 Million Series A Financing to Establish a Chinese Joint Venture, Zentera Therapeutics GlobeNewswire -8.04%
May-15-20 07:00AM	Zentalis Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational Update GlobeNewswire -5.51%
May-13-20 09:30AM	Morgan Stanley: 2 Stocks That Could Surge Over 25% TipRanks
Apr-30-20 07:00AM	Zentalis Pharmaceuticals Announces FDA Clearance of IND Application for ZN-d5 for the Treatment of Hematologic Malignancies GlobeNewswire
Apr-07-20 04:05PM	Zentalis Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Apr-02-20 09:22PM	Zentalis Pharmaceuticals Announces Pricing of Initial Public Offering GlobeNewswire

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bunker Kevin D.	Chief Operating Officer	Apr 11	Sale	30.55	5,000	152,745	135,000	Apr 13 05:53 PM
Gallagher Cam	Director	Apr 05	Sale	50.48	10,000	504,769	355,813	Apr 05 06:52 PM
SUN ANTHONY Y	President & CEO	Apr 05	Sale	51.52	10,471	539,474	1,175,589	Apr 05 06:52 PM
SUN ANTHONY Y	President & CEO	Apr 04	Sale	48.50	10,471	507,844	1,186,060	Apr 05 06:52 PM
Epperly Melissa B,	Chief Financial Officer	Apr 04	Sale	50.09	17,080	855,522	247,414	Apr 05 06:53 PM
Bunker Kevin D.	Chief Operating Officer	Mar 21	Sale	49.07	10,000	490,670	140,000	Mar 21 07:55 PM
Gallagher Cam	Director	Mar 15	Sale	41.92	10,000	419,241	365,813	Mar 16 05:18 PM
Bunker Kevin D.	Chief Operating Officer	Mar 10	Sale	46.94	10,000	469,374	150,000	Mar 10 05:41 PM
Gallagher Cam	Director	Mar 07	Sale	44.94	10,000	449,387	375,813	Mar 08 07:43 PM
SUN ANTHONY Y	President & CEO	Mar 02	Sale	50.16	10,471	525,265	1,196,531	Mar 03 05:11 PM
SUN ANTHONY Y	President & CEO	Mar 01	Sale	49.79	10,471	521,384	1,207,002	Mar 03 05:11 PM
Epperly Melissa B,	Chief Financial Officer	Feb 23	Sale	49.10	1,913	93,921	264,494	Feb 23 08:12 PM
Bunker Kevin D.	Chief Operating Officer	Feb 22	Sale	49.09	10,000	490,933	160,000	Feb 23 08:12 PM
Gallagher Cam	Director	Feb 15	Sale	51.93	10,000	519,295	385,813	Feb 15 06:35 PM
Pinto Alexis	Chief Legal Officer	Feb 14	Sale	50.23	691	34,708	22,240	Feb 14 09:10 PM
Voliotis Dimitris	SVP, Clinical Development	Feb 14	Sale	50.23	601	30,188	15,978	Feb 14 09:10 PM
Gallagher Cam	Director	Feb 14	Sale	50.19	7,188	360,775	395,813	Feb 14 09:09 PM
SUN ANTHONY Y	President & CEO	Feb 14	Sale	50.23	4,733	237,733	1,217,473	Feb 14 09:08 PM
Bunker Kevin D.	Chief Operating Officer	Feb 14	Sale	50.26	4,688	235,638	764,110	Feb 14 09:11 PM
Bunker Kevin D.	Chief Operating Officer	Feb 10	Sale	53.50	10,000	534,995	170,000	Feb 14 09:11 PM
Gallagher Cam	Director	Feb 07	Sale	53.45	10,000	534,474	387,203	Feb 07 09:53 PM
SUN ANTHONY Y	President & CEO	Feb 02	Sale	57.97	10,471	606,966	1,171,775	Feb 03 08:03 PM
SUN ANTHONY Y	President & CEO	Feb 01	Sale	57.58	10,471	602,926	1,182,246	Feb 03 08:03 PM
Voliotis Dimitris	SVP, Clinical Development	Jan 20	Option Exercise	18.00	10,000	180,000	16,250	Jan 20 07:15 PM
Bunker Kevin D.	Chief Operating Officer	Jan 20	Sale	59.99	10,000	599,912	180,000	Jan 20 07:14 PM
Voliotis Dimitris	SVP, Clinical Development	Jan 20	Sale	60.63	10,000	606,323	6,250	Jan 20 07:15 PM
Voliotis Dimitris	SVP, Clinical Development	Jan 19	Option Exercise	18.00	10,000	180,000	16,250	Jan 20 07:15 PM
Voliotis Dimitris	SVP, Clinical Development	Jan 19	Sale	60.79	10,000	607,931	6,250	Jan 20 07:15 PM
Voliotis Dimitris	SVP, Clinical Development	Jan 18	Option Exercise	18.00	10,000	180,000	16,250	Jan 20 07:15 PM
Gallagher Cam	Director	Jan 18	Sale	62.64	10,000	626,376	397,203	Jan 19 07:21 PM
Voliotis Dimitris	SVP, Clinical Development	Jan 18	Sale	62.65	10,000	626,491	6,250	Jan 20 07:15 PM
Bunker Kevin D.	Chief Operating Officer	Jan 10	Sale	68.41	10,000	684,097	190,000	Jan 11 06:55 PM
Gallagher Cam	Director	Jan 05	Sale	75.49	10,000	754,861	407,203	Jan 05 05:49 PM
SUN ANTHONY Y	President & CEO	Jan 04	Sale	78.68	10,471	823,870	1,192,717	Jan 05 05:49 PM
Blackwell Kimberly	Director	Jan 03	Option Exercise	47.80	1,000	47,800	6,000	Jan 05 05:49 PM
Blackwell Kimberly	Director	Jan 03	Sale	83.74	1,000	83,740	5,000	Jan 05 05:49 PM
SUN ANTHONY Y	President & CEO	Jan 03	Sale	80.07	10,471	838,438	1,203,188	Jan 05 05:49 PM
Bunker Kevin D.	Chief Operating Officer	Dec 20	Sale	79.24	10,000	792,431	200,000	Dec 21 06:17 PM
Gallagher Cam	Director	Dec 15	Sale	74.03	10,000	740,337	417,203	Dec 16 05:18 PM
Bunker Kevin D.	Chief Operating Officer	Dec 10	Sale	71.71	10,000	717,106	210,000	Dec 13 06:09 PM
Gallagher Cam	Director	Dec 06	Sale	71.33	10,000	713,300	427,203	Dec 07 08:35 PM
SUN ANTHONY Y	President & CEO	Dec 02	Sale	76.78	10,471	803,992	1,103,659	Dec 02 07:16 PM
Blackwell Kimberly	Director	Dec 01	Option Exercise	47.80	1,000	47,800	6,000	Dec 02 07:16 PM
SUN ANTHONY Y	President & CEO	Dec 01	Sale	77.98	10,471	816,536	1,114,130	Dec 02 07:16 PM
Blackwell Kimberly	Director	Dec 01	Sale	81.84	1,000	81,840	5,000	Dec 02 07:16 PM
Bunker Kevin D.	Chief Operating Officer	Nov 22	Sale	75.99	10,000	759,937	220,000	Nov 23 04:45 PM
Gallagher Cam	Director	Nov 15	Sale	75.36	10,000	753,619	437,203	Nov 16 07:11 PM
Bunker Kevin D.	Chief Operating Officer	Nov 10	Sale	78.15	10,000	781,471	230,000	Nov 12 04:38 PM
Gallagher Cam	Director	Nov 05	Sale	82.95	10,000	829,491	447,203	Nov 05 09:12 PM
SUN ANTHONY Y	President & CEO	Nov 02	Sale	80.47	10,471	842,602	1,249,601	Nov 02 07:24 PM
Blackwell Kimberly	Director	Nov 01	Option Exercise	47.80	1,000	47,800	6,000	Nov 02 07:24 PM
Blackwell Kimberly	Director	Nov 01	Sale	80.46	1,000	80,460	5,000	Nov 02 07:24 PM
SUN ANTHONY Y	President & CEO	Nov 01	Sale	81.44	10,471	852,772	1,260,072	Nov 02 07:24 PM
Pinto Alexis	Chief Legal Officer	Oct 25	Option Exercise	34.40	30,000	1,032,000	36,526	Oct 27 08:13 PM
Blackwell Kimberly	Director	Oct 25	Option Exercise	47.80	1,000	47,800	6,000	Oct 27 08:13 PM
Blackwell Kimberly	Director	Oct 25	Sale	77.59	1,000	77,590	5,000	Oct 27 08:13 PM
Pinto Alexis	Chief Legal Officer	Oct 25	Sale	77.73	30,000	2,332,002	6,526	Oct 27 08:13 PM
SUN ANTHONY Y	President & CEO	Oct 04	Sale	66.33	26,799	1,777,707	1,270,543	Oct 04 09:15 PM
Johnson David Michael	Director	Oct 04	Sale	66.35	12,896	855,588	80,959	Oct 04 09:15 PM
Bunker Kevin D.	Chief Operating Officer	Oct 01	Sale	66.13	8,420	556,856	0	Oct 04 09:16 PM
Gallagher Cam	Director	Oct 01	Sale	66.15	10,000	661,490	457,203	Oct 04 09:17 PM
SUN ANTHONY Y	President & CEO	Sep 01	Sale	67.50	26,794	1,808,716	1,297,342	Sep 02 07:32 PM
Gallagher Cam	Director	Sep 01	Sale	67.52	10,000	675,229	467,203	Sep 02 07:32 PM
Bunker Kevin D.	Chief Operating Officer	Sep 01	Sale	67.49	8,420	568,283	8,420	Sep 02 07:31 PM
Epperly Melissa B,	Chief Financial Officer	Aug 19	Buy	52.00	8,285	430,800	266,685	Aug 20 12:59 PM
Epperly Melissa B,	Chief Financial Officer	Aug 18	Buy	52.00	1,326	68,948	258,400	Aug 20 12:59 PM
SUN ANTHONY Y	President & CEO	Aug 03	Sale	50.53	7,779	393,090	1,324,136	Aug 03 08:01 PM
SUN ANTHONY Y	President & CEO	Aug 02	Sale	51.03	19,015	970,247	1,331,915	Aug 03 08:01 PM
Gallagher Cam	Director	Aug 02	Sale	51.02	10,000	510,198	477,203	Aug 03 07:59 PM
Bunker Kevin D.	Chief Operating Officer	Aug 02	Sale	51.05	8,420	429,805	16,840	Aug 03 07:59 PM
SUN ANTHONY Y	President & CEO	Jul 07	Sale	47.13	17,804	839,114	1,350,930	Jul 08 04:56 PM
Gallagher Cam	Director	Jul 07	Sale	47.13	2,572	121,220	499,382	Jul 08 04:55 PM
Bunker Kevin D.	Chief Operating Officer	Jul 07	Sale	47.13	4,514	212,748	1,008,788	Jul 08 04:55 PM
Bunker Kevin D.	Chief Operating Officer	Jul 06	Sale	46.90	20,298	951,927	994,841	Jul 08 04:55 PM
Gallagher Cam	Director	Jul 06	Sale	46.88	15,798	740,636	487,203	Jul 08 04:55 PM
SUN ANTHONY Y	President & CEO	Jul 06	Sale	46.90	25,045	1,174,488	1,368,734	Jul 08 04:56 PM
Gallagher Cam	Director	Jul 02	Sale	49.58	10,000	495,827	505,573	Jul 06 08:00 PM
SUN ANTHONY Y	President & CEO	Jul 01	Sale	51.21	26,794	1,372,235	1,393,779	Jul 06 08:00 PM
Epperly Melissa B,	Chief Financial Officer	Jul 01	Sale	51.27	3,083	158,054	257,074	Jul 06 08:01 PM
Bunker Kevin D.	Chief Operating Officer	Jul 01	Sale	51.23	8,420	431,367	25,260	Jul 06 08:01 PM
Bunker Kevin D.	Chief Operating Officer	Jun 01	Sale	54.09	8,420	455,442	33,680	Jun 02 08:26 PM
Gallagher Cam	Director	Jun 01	Sale	54.06	10,000	540,551	515,573	Jun 02 08:27 PM
SUN ANTHONY Y	President & CEO	Jun 01	Sale	54.03	26,794	1,447,679	1,420,573	Jun 02 08:26 PM
Epperly Melissa B,	Chief Financial Officer	Jun 01	Sale	54.05	3,083	166,641	260,157	Jun 02 08:26 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience